Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s fair to say that there’s change afoot at Brooklyn Immunotherapeutics (NYSEAMERICAN: BTX ). Some folks are averse to big changes, but BTX stock holders shouldn’t be worried at all. Source:...
Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) ("Brooklyn" or the “Company”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogen...
Brooklyn ImmunoTherapeutics (BTX) announces a publication in Breast Cancer Research that demonstrates how multiplex immunofluorescence (mIF) may be used to characterize the immunological activity of IRX-2 in early stage breast cancer.Multiplex immunofluorescence combined with hierarchical lin...
Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced a publication in Breast Cancer...
There seems to be a short squeeze at Brooklyn, although I’m skeptical the source is the WallStreetBets subreddit as many claim. Short squeezes rarely last long and also the company is selling shares, which is a very good scenario to take a short position through put options. ...
Brooklyn ImmunoTherapeutics (NYSEMKT: BTX) , a relative newcomer to the world of publicly traded biotech stocks, saw its shares rip higher in April by a stunning 1,230%, according to data provided by S&P Global Market Intelligence . The stock took flight last month for ...
Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders and monogenic diseases, today announced the appointm...
Esperion Therapeutics (ESPR) -32% on Q1 earnings release.Cocrystal Pharma (COCP) -27% after launches $40M stock offering.SemiLEDs (LEDS) -21%.Mercury Systems (MRCY) -18% on FQ3 earnings release.Adamis Pharmaceuticals (ADMP) -14%.Reed's (REED) -14% after...
Brooklyn ImmunoTherapeutics (NYSEMKT: BTX) was a little-known biotech trading at $4 per share last month. As of May 4, however, its share price has rocketed to $55. Brooklyn ImmunoTherapeutics is now a mid cap with a market capitalization of nearly $2.7 billion -- and growing. It ha...
Best Health Care Stocks To Buy Right Now? 4 In Focus Health care stocks have been on a tear in the stock market . No matter what’s happening elsewhere in the economy, the health care industry will likely continue to work towards improving our quality of life. With this be...
News, Short Squeeze, Breakout and More Instantly...
Brooklyn ImmunoTherapeutics Inc. Company Name:
BTX Stock Symbol:
NYSE Market:
Brooklyn ImmunoTherapeutics Inc. Website:
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s...
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnos...
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today ann...